Medical Device Combines Nanotechnology to Diagnose Kidney Disease
By LabMedica International staff writers Posted on 17 Mar 2015 |

Image: The quantitative electrochemical lateral flow assay (QELFA) device (Photo courtesy of Somersault 18:24).
A new medical device which combines nanotechnology with a pregnancy tester could help diagnose and treat the one million people in the UK who don't know they have kidney disease.
Every day 19 people in the UK are diagnosed with kidney failure yet there is currently no device that can be used by doctors for day-to-day monitoring of kidney disease and four of the 19 people will not have visited specialist services for sufficient time to prepare for their treatment.
The apparatus is a quantitative electrochemical lateral flow assay (QELFA) and uses nanoparticles to test the patient's urine giving results in seconds. It is linked via mobile technology so doctors can track how the disease is developing. The devise was developed by engineers and costs about GBP 10 can be used at home and could revolutionize kidney disease care in the UK, which currently costs the UK National Health Service (NHS) over GBP 1.4 billion, more than breast, lung, colon and skin cancer combined.
The devise which works like a pregnancy test was created by Bio Nano Consulting (London, UK). The digital readout of the test enables the automatic and accurate collation of kidney-function readings into a central database using mobile technology. Behind the patients who develop kidney failure and in need of rapid diagnosis are many more who will have a lesser degree of kidney dysfunction, called Chronic Kidney Disease (CKD), that will place them at increased risk of cardiovascular disease and acute kidney injury.
Helen Meese CEng, MIMech, PhD, Head of Materials at the Institution of Mechanical Engineers (London, UK), said, “The QELFA device is a brilliant example of what's possible. Using an old technology like a pregnancy tester and combining it with nanotechnology, you have a device which could not only diagnose the million people in the UK who are unaware they have kidney disease, but also help doctors effectively monitor those undergoing treatment. It could also save the NHS millions of pounds a year. But although the UK has been at the forefront of nanotechnology development, we still lag behind in its commercialization and many people are still unsure of its potential. We must change this.”
Related Links:
Bio Nano Consulting
Institution of Mechanical Engineers
Every day 19 people in the UK are diagnosed with kidney failure yet there is currently no device that can be used by doctors for day-to-day monitoring of kidney disease and four of the 19 people will not have visited specialist services for sufficient time to prepare for their treatment.
The apparatus is a quantitative electrochemical lateral flow assay (QELFA) and uses nanoparticles to test the patient's urine giving results in seconds. It is linked via mobile technology so doctors can track how the disease is developing. The devise was developed by engineers and costs about GBP 10 can be used at home and could revolutionize kidney disease care in the UK, which currently costs the UK National Health Service (NHS) over GBP 1.4 billion, more than breast, lung, colon and skin cancer combined.
The devise which works like a pregnancy test was created by Bio Nano Consulting (London, UK). The digital readout of the test enables the automatic and accurate collation of kidney-function readings into a central database using mobile technology. Behind the patients who develop kidney failure and in need of rapid diagnosis are many more who will have a lesser degree of kidney dysfunction, called Chronic Kidney Disease (CKD), that will place them at increased risk of cardiovascular disease and acute kidney injury.
Helen Meese CEng, MIMech, PhD, Head of Materials at the Institution of Mechanical Engineers (London, UK), said, “The QELFA device is a brilliant example of what's possible. Using an old technology like a pregnancy tester and combining it with nanotechnology, you have a device which could not only diagnose the million people in the UK who are unaware they have kidney disease, but also help doctors effectively monitor those undergoing treatment. It could also save the NHS millions of pounds a year. But although the UK has been at the forefront of nanotechnology development, we still lag behind in its commercialization and many people are still unsure of its potential. We must change this.”
Related Links:
Bio Nano Consulting
Institution of Mechanical Engineers
Latest Technology News
- Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine
- Rapid Diagnostic Technology Utilizes Breath Samples to Detect Lower Respiratory Tract Infections
- Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes
- Wireless Sweat Patch Could Be Used as Diagnostic Test for Cystic Fibrosis
- New Method Advances AI Reliability with Applications in Medical Diagnostics
- Self-Powered Microneedle Patch Collects Biomarker Samples Without Drawing Blood
- Skin Patch Detects Biomarkers in Interstitial Fluid Without Blood Draws
- Handheld Saliva Test Accurately Detects Breast Cancer
- Cutting-Edge AI Algorithms Enable Early Detection of Prostate Cancer
- New Microfluidic System Enables Early Cancer Diagnosis Using Simple Blood Tests
Channels
Clinical Chemistry
view channel
Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
Ovarian cancer is considered one of the deadliest cancers, in part because it rarely shows clear symptoms in its early stages, and diagnosis is often complex. Current approaches make it difficult to accurately... Read more
Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read moreMolecular Diagnostics
view channel
New DNA Methylation-Based Method Predicts Cancer Progression
Cancer often develops silently for years before diagnosis, making it difficult to trace its origins and predict its progression. Traditional approaches to studying cancer evolution have lacked the precision... Read more
Urine Test Could Predict Outcome of Cartilage Transplant Surgery
Cartilage transplant surgery provides an alternative to artificial joint replacements by using donor tissue to restore knee function. While many patients benefit, outcomes can vary, leaving uncertainty... Read more
2-Hour Cancer Blood Test to Transform Tumor Detection
Glioblastoma and other aggressive cancers remain difficult to control largely because tumors can recur after treatment. Current diagnostic methods, such as invasive biopsies or expensive liquid biopsies,... Read more
Automated High Throughput Immunoassay Test to Advance Neurodegenerative Clinical Research
Alzheimer’s disease and other neurodegenerative disorders remain difficult to diagnose and monitor accurately due to limitations in existing biomarkers. Traditional tau and phosphorylated tau measurements... Read moreHematology
view channel
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more
Platelets Could Improve Early and Minimally Invasive Detection of Cancer
Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more
Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read moreImmunology
view channel
Novel Tool Uses Deep Learning for Precision Cancer Therapy
Nearly 50 new cancer therapies are approved each year, but selecting the right one for patients with highly individual tumor characteristics remains a major challenge. Physicians struggle to navigate the... Read more
Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients
Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read moreMicrobiology
view channel
Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
Sepsis arises from infection and immune dysregulation, with neutrophils playing a central role in its progression. However, current clinical tools are unable to both isolate these cells and assess their... Read more
New Diagnostic Method Confirms Sepsis Infections Earlier
Sepsis remains one of the most dangerous medical emergencies, often progressing rapidly and becoming fatal without timely intervention. Each hour of delayed treatment in septic shock reduces patient survival... Read more
New Markers Could Predict Risk of Severe Chlamydia Infection
Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Portable Spectroscopy Rapidly and Noninvasively Detects Bacterial Species in Vaginal Fluid
Vaginal health depends on maintaining a balanced microbiome, particularly certain Lactobacillus species. Disruption of this balance, known as dysbiosis, can increase risks of infection, pregnancy complications,... Read morePathology
view channel
ESR Testing Breakthrough Extends Blood Sample Stability from 4 to 28 Hours
Erythrocyte sedimentation rate (ESR) is one of the most widely ordered blood tests worldwide, helping clinicians detect and monitor infections, autoimmune conditions, cancers, and other diseases.... Read more
Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma
Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more
Clinicopathologic Study Supports Exclusion of Cervical Serous Carcinoma from WHO Classification
High-grade serous carcinoma is a rare diagnosis in cervical biopsies and can be difficult to distinguish from other tumor types. Cervical serous carcinoma is no longer recognized as a primary cervical... Read moreIndustry
view channel
VedaBio Partners With Mammoth Biosciences to Expand CRISPR-Based Diagnostic Technologies
VedaBio (San Diego, CA, USA) has entered into a non-exclusive license agreement with Mammoth Biosciences (Brisbane, CA, USA) for the use of select CRISPR-based technologies in diagnostic applications.... Read more